Anthony Caggiano, Chief Medical Officer at COGNITION THERAPEUTICS INC (CGTX), bought 10,000 shares at $1.11 ($11K) on 2026-04-16, disclosed to the SEC on 2026-04-20.
CMO Anthony Caggiano purchased 10,000 shares at $1.11, marking the largest purchase of his career and a reversal after five consecutive sales. This move comes as the stock has rallied 15% over the last five days despite a 20% decline over the past quarter.
The stock is currently trading at $1.12, up 14.94% over the last five days but still down 20.0% over the past 90 days. It remains significantly below its 52-week high of $3.83, trading roughly 70.76% below that peak.
The reversal follows five consecutive sales by the insider; the purchase is the largest in the company's history. Management highlighted progress advancing zervimesine into late-stage development at the Needham conference on April 13, 2026. Additionally, the Q4 2025 earnings call on March 26, 2026, outlined a shift in development priorities for the lead candidate.
The stock carries high volatility with a beta of 1.813 and a short interest of 9.68% of the float. It is also trading at a negative forward P/E of -4.34, indicating unprofitability.
Something here stands out, but not much.